- A class action lawsuit has been filed against **Unicycive Therapeutics, Inc.** and certain officers for alleged violations of federal securities laws during the period of **March 29, 2024, and June 27, 2025**.  **[1766140_20250923DC80145:0]** 
- The lawsuit claims that Unicycive made materially false and misleading statements regarding its ability to meet FDA manufacturing compliance requirements for its drug, **oxylanthanum carbonate (OLC)**.  **[1766140_20250923DC80145:0]** 
- On **June 10, 2025**, Unicycive's stock price fell **40.89%** after the company disclosed FDA-identified deficiencies in cGMP compliance at a third-party manufacturing vendor.  **[1766140_20250923DC80145:0]** 
- The FDA issued a Complete Response Letter (CRL) for the OLC New Drug Application (NDA) on **June 30, 2025**, citing these deficiencies, which resulted in an additional **29.85%** drop in Unicycive's stock price.  **[1766140_20250923DC80145:0]** 
- Investors who acquired Unicycive securities during the class period have until **October 14, 2025**, to seek appointment as Lead Plaintiff.  **[1766140_20250923DC80145:0]**

Unicycive Therapeutics Faces Class Action Lawsuit

- A class action lawsuit has been filed against **Unicycive Therapeutics, Inc.** and certain officers by Pomerantz LLP, on behalf of investors who purchased securities between **March 29, 2024, and June 27, 2025**.  **[1766140_20250918DC75017:0]** 
- The lawsuit alleges that defendants made materially false and misleading statements regarding the company's readiness to satisfy FDA manufacturing compliance requirements and the regulatory prospects of its oxylanthanum carbonate (OLC) New Drug Application (NDA).  **[1766140_20250918DC75017:0]** 
- Key events cited include the FDA's identification of cGMP compliance deficiencies at a third-party vendor on **June 10, 2025**, which caused Unicycive's stock price to fall **40.89%**, and the subsequent issuance of a Complete Response Letter (CRL) for the OLC NDA on **June 30, 2025**, leading to an additional **29.85%** stock price decline.  **[1766140_20250918DC75017:0]** 
- Investors who purchased Unicycive securities during the Class Period have until **October 14, 2025**, to ask the Court to appoint them as Lead Plaintiff.  **[1766140_20250918DC75017:0]**

- Bragar Eagel & Squire, P.C. has commenced a class action lawsuit against **Unicycive (NASDAQ:UNCY)**, with a class period from **March 29, 2024, through June 27, 2025**.  **[1766140_93489d2f11a74353a9044dcd053cd747_0]** 
- The lawsuit alleges that Unicycive overstated its readiness and ability to satisfy the U.S. Food and Drug Administration's (FDA) manufacturing compliance requirements for its New Drug Application (NDA) for oxylanthanum carbonate (OLC).  **[1766140_93489d2f11a74353a9044dcd053cd747_0]** 
- This alleged overstatement led to significant stock price declines, including **over 40%** on June 10, 2025, and **almost 30%** on June 30, 2025, when the FDA issued a Complete Response Letter for the OLC NDA, with the stock closing at **$4.77 per share** on that date.  **[1766140_93489d2f11a74353a9044dcd053cd747_0]** 
- The deadline for stockholders to petition the court to serve as lead plaintiff is **October 14, 2025**.  **[1766140_93489d2f11a74353a9044dcd053cd747_0]**

Unicycive Faces Shareholder Class Action Lawsuit

- Grabar Law Office is investigating Unicycive Therapeutics, Inc. for alleged **breach of fiduciary duties** by certain officers and directors.  **[1766140_6c94955620074c88a35baaea97262d8a_3]** 
- A federal securities fraud class action complaint alleges the company **overstated its readiness** to meet FDA manufacturing compliance and the **regulatory prospects** of its oxylanthanum carbonate new drug application.  **[1766140_6c94955620074c88a35baaea97262d8a_3]** 
- Shareholders who purchased shares **prior to March 29, 2024**, and still hold them, can seek corporate reforms; those who purchased between **March 29, 2024, and June 27, 2025**, can participate in the class action.  **[1766140_6c94955620074c88a35baaea97262d8a_3]**

Unicycive Therapeutics Faces Shareholder Investigation

- **Faruqi & Faruqi, LLP** is investigating **Unicycive Therapeutics** for potential federal securities law violations, alleging the company made false or misleading statements regarding its readiness to satisfy **FDA** manufacturing compliance requirements and the regulatory prospects of its **OLC NDA**.  **[1766140_ac2fc027e79d4b4589e363ac2f134e09_1]** 
- The investigation stems from two significant stock price drops: on **June 10, 2025**, the stock fell **$3.68 per share**, or **40.89%**, to **$5.32 per share** after the **FDA** identified manufacturing deficiencies, and on **June 30, 2025**, it fell an additional **$2.03 per share**, or **29.85%**, to **$4.77 per share** following a **Complete Response Letter** for the **OLC NDA** due to the same issues.  **[1766140_ac2fc027e79d4b4589e363ac2f134e09_1]** 
- Investors who purchased or acquired **Unicycive** securities between **March 29, 2024, and June 27, 2025**, may be affected, and the deadline to seek the role of lead plaintiff in the federal securities class action is **October 14, 2025**.  **[1766140_ac2fc027e79d4b4589e363ac2f134e09_0]** **[1766140_ac2fc027e79d4b4589e363ac2f134e09_1]**

Faruqi & Faruqi Investigates Unicycive Therapeutics for Securities Violations

- Bragar Eagel & Squire, P.C. has commenced a class action lawsuit against Unicycive (NASDAQ:UNCY) on behalf of stockholders.  **[1766140_ebdc8d0b64024bd198141e6676661952_0]** 
- The class period for the lawsuit is **March 29, 2024, through June 27, 2025**, with a lead plaintiff deadline of **October 14, 2025**.  **[1766140_ebdc8d0b64024bd198141e6676661952_0]** 
- The complaint alleges that Unicycive overstated its readiness and ability to satisfy the U.S. Food and Drug Administration's (FDA) manufacturing compliance requirements for its oxylanthanum carbonate (OLC) New Drug Application (NDA).  **[1766140_ebdc8d0b64024bd198141e6676661952_0]** 
- On **June 10, 2025**, Unicycive announced the FDA identified deficiencies in cGMP compliance at a third-party manufacturing vendor, causing the stock price to fall **over 40%**.  **[1766140_ebdc8d0b64024bd198141e6676661952_0]** 
- On **June 30, 2025**, the FDA issued a Complete Response Letter for the OLC NDA, citing the previously identified cGMP deficiencies, which led to an almost **30%** stock price drop, closing at **$4.77 per share**.  **[1766140_ebdc8d0b64024bd198141e6676661952_0]**

Unicycive Therapeutics (UNCY)